Papers
9
Total Citations
141
H-Index
6
About
Qingyang Feng is a prominent surgical researcher specializing in minimally invasive and robotic surgery for colorectal cancer, with a particular focus on middle and low rectal cancer. Based at Zhongshan Hospital in China, Feng has made substantial contributions to understanding the comparative efficacy of robotic, laparoscopic, and open surgical approaches for rectal cancer treatment. Feng's most impactful work centers on the landmark REAL trial — a multicenter randomized controlled trial comparing robotic and laparoscopic surgery for middle and low rectal cancer — with the short-term outcomes paper garnering 9 citations and the 2025 long-term outcomes paper already accumulating an impressive 79 citations, underscoring its immediate significance to the field. Earlier single-center randomized controlled trial work examining abdominoperineal resections further established Feng's credentials in rigorous clinical trial methodology. Beyond comparative surgical outcomes, Feng has contributed meaningfully to identifying risk factors for anastomotic leakage following robotic rectal surgery, providing clinicians with actionable guidance for high-risk patients. Feng has also helped contextualize the adoption of robotic colorectal surgery within China through review work examining national trends. Collectively, Feng's research has helped generate the high-quality evidence base needed to validate robotic surgery's role in rectal cancer care.
Research Focus
Key Achievements
Top Papers
- 1Robotic vs Laparoscopic Surgery for Middle and Low Rectal Cancer79 citations · 2025
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9